Jakinibs of All Trades: Inhibiting Cytokine Signaling in Immune-Mediated Pathologies

Jakinibs of All Trades: Inhibiting Cytokine Signaling in Immune-Mediated Pathologies

Over the last 25 years, inhibition of Janus kinases (JAKs) has been pursued as a modality for treating various immune and inflammatory disorders. While the clinical development of JAK inhibitors (jakinibs) began with the investigation of their use in allogeneic transplantation, their widest successf...

Full description

Bibliographic Details
Main Authors: Madison Alexander, Yiming Luo, Giorgio Raimondi, John J. O’Shea, Massimo Gadina
Format: Article
Language:English
Published: MDPI AG 2021-12-01
Series:Pharmaceuticals
Subjects:
JAK
cytokines
inflammation
autoimmune diseases
COVID-19
Online Access:https://www.mdpi.com/1424-8247/15/1/48

Similar Items

Similar Items